Oral selenium improved the disease activity in patients with mild Graves’ orbitopathy

Almanza-Monterrubio, M.; Garnica-Hayashi, Lilia; Dávila-Camargo, A.; Nava-Castañeda, Ángel

doi:10.1016/j.jfo.2020.08.029

Cited by 11 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pre-treatment values showed no statistically significant differences between groups. At the end of the treatment the supplemented group showed statistically significant differences in CAS score (which consists of seven inflammatory signs referred to the eyes) while no differences were found in any variables in the placebo group [ 167 ].…”

Section: Thyroid Diseasementioning

confidence: 99%

The Role of Selenium in Pathologies: An Updated Review

2022

View full text Add to dashboard Cite

Selenium is an essential microelement required for a number of biological functions. Selenium—and more specifically the amino acid selenocysteine—is present in at least 25 human selenoproteins involved in a wide variety of essential biological functions, ranging from the regulation of reactive oxygen species (ROS) concentration to the biosynthesis of hormones. These processes also play a central role in preventing and modulating the clinical outcome of several diseases, including cancer, diabetes, Alzheimer’s disease, mental disorders, cardiovascular disorders, fertility impairments, inflammation, and infections (including SARS-CoV-2). Over the past years, a number of studies focusing on the relationship between selenium and such pathologies have been reported. Generally, an adequate selenium nutritional state—and in some cases selenium supplementation—have been related to improved prognostic outcome and reduced risk of developing several diseases. On the other hand, supra-nutritional levels might have adverse effects. The results of recent studies focusing on these topics are summarized and discussed in this review, with particular emphasis on advances achieved in the last decade.

show abstract

Section: Thyroid Diseasementioning

confidence: 99%

The Role of Selenium in Pathologies: An Updated Review

2022

View full text Add to dashboard Cite

show abstract

“…TSH receptor antibodies (TRAbs) have been shown to be involved in the pathogenesis and course of GO and are strongly correlated with activity and severity (17)(18)(19). Studies have shown that selenium plays an active role in GO because of its antioxidant and immunoregulatory abilities (13,20,21). In this study, starting from 3 months of intervention, patients treated with selenium had better improvement in ocular symptoms and signs and a gradual decline in clinical activity score and TRAb levels, even after drug withdrawal, which was not seen in the placebo group.…”

Section: Discussionmentioning

confidence: 99%

Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study

Wang,

Qiao,

Liu

et al. 2024

Endocrine

View full text Add to dashboard Cite

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease. However, limited studies have investigated the actual e cacy of selenium in GO therapy. This longitudinal study explored the effect of selenium on QOL and prognosis of patients with mild-to-moderate GO. MethodsWe conducted a 5-year prospective controlled cohort clinical trial to determine the effect of selenium on 74 patients with mild-to-moderate GO. Patients received selenium yeast or placebo orally for 6 months and were followed up at 6 months and at 5 years by biochemical examination, ophthalmologist evaluation and QOL questionnaire to assess oculopathy and QOL. Results(1) During a follow-up period of 3-6 months, in the selenium group, the symptoms of tearing, grittiness and conjunctival congestion improved (P < 0.01); clinical activity scores and total GO-QOL scores increased relative to baseline (P < 0.01); TRAb was decreased at the 6-month evaluation (P = 0.003); and patients treated with selenium had a higher rate of improvement and a lower rate of worsening than patients treated with placebo (P < 0.05). ( 2) Exploratory evaluations at 6 months after drug withdrawal con rmed the earlier results; further changes included alleviation of blurred vision and diplopia symptoms in the selenium group (P < 0.01). (3) At the 5-year follow-up, compared with baseline, ocular symptoms and signs, proptosis, clinical activity scores, TRAb level and total GO-QOL scores in both the selenium and placebo groups were signi cantly improved (P < 0.01). ConclusionSix months of selenium supplementation may effectively change the early course of mild-to-moderate GO, but this regimen makes no difference in long-term outcomes.

show abstract

“…The reason for these inconsistent effects is not yet well understood but may be linked to the baseline Se status 12,13 . Positive effects of Se supplementation have consistently been observed in GD and are included in clinical practice in countries with borderline Se de ciency [14][15][16][17][18] .…”

Section: Introductionmentioning

confidence: 99%

A follow-up study on factors affecting the rehabilitation of patients with hypothyroidism in different selenium environments

Wang,

Chen,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Hypothyroidism is a key manifestation of autoimmune thyroid disease (AITD). Our previous research has found that low selenium (Se) status was linked to an elevated prevalence and incidence of thyroid diseases. We hypothesized that Se status may also influence the restoration of thyroid function. Thus, our study aims to investigate the factors affecting the recovery of thyroid function in patients with (sub-)clinical hypothyroidism, with a specific focus on Se status.Methods We conducted a 6-year prospective cohort study comparing different Se concentration regions. Demographic and disease data were collected from 1190 subjects (549 Se-adequate and 641 Se-deficient), who successfully completed the follow-up study in 2019. Additionally, urinary iodine (I) levels, thyroid function, and serum and nail Se levels were measured. We used logistic regression to investigate the relationship between Se deficiency and thyroid function recovery.Results Two counties were similar in sex, smoking status. The recovery rate of thyroid function was significantly higher in Se-deficient counties (46.0% vs. 30.6%, P = 0.008). In multivariate analysis, our results show that female sex [OR (95%CI) = 1.977 (1.279–3.055), P = 0.002] and increasing age [OR (95%CI) = 1.027 (1.007–1.047), P = 0.007] were associated with the recovery rate. Additionally, our study revealed that while the Se status was significant in univariate analysis, this association appeared to fade in multivariate analysis.Conclusions Female sex and increasing age have unfavorable effects on the recovery of thyroid function in patients with (sub-)clinical hypothyroidism who are over 30 years old.

show abstract

Oral selenium improved the disease activity in patients with mild Graves’ orbitopathy

Cited by 11 publications

References 12 publications

The Role of Selenium in Pathologies: An Updated Review

The Role of Selenium in Pathologies: An Updated Review

Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study

A follow-up study on factors affecting the rehabilitation of patients with hypothyroidism in different selenium environments

Contact Info

Product

Resources

About